NICE endorses coronary stents
This article was originally published in The Gray Sheet
Executive Summary
J&J Cypher and Boston Scientific Taxus drug-eluting stents are recommended for coronary artery disease where percutaneous intervention is clinically appropriate for symptomatic angina/acute myocardial infarction with target arteries less than 3 mm in diameter or lesions longer than 15 mm, UK's National Institute for Clinical Excellence states in a recent final appraisal determination. NICE issued its preliminary recommendations for coronary stents in June (1"The Gray Sheet" June 30, 2003, p. 10)...
You may also be interested in...
NICE endorses drug-eluting stents
UK National Institute for Clinical Excellence issues Oct. 22 1guidance on the use of DES, culminating an 18-month review process. The guidance follows a September final appraisal determination (2"The Gray Sheet" Sept. 22, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.